A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

In March 2014, Regeneron filed a patent infringement suit in the Southern District of New York against Dutch biotech firm Merus (NASDAQ:MRUS) to remedy Merus’ infringement of the ‘018 patent ...

In one example of a lucrative patent thicket, AbbVie notoriously gained more than 100 patents on its megablockbuster Humira. Despite complaints, a court found the strategy legal .

Regeneron has a very strong pipeline ... EYLEA revenue after patent expiration. Regeneron has been generating an impressive amount of ... its immuno-oncology development strategy.

Oct 4 - Biotech company Regeneron Pharmaceuticals (REGN.O), opens new tab lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 ...

Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York federal court.

As we have previously reported, Regeneron’s BPCIA case against Mylan regarding Mylan’s proposed aflibercept biosimilar is proceeding on an expedited schedule, with a two-week trial scheduled ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.

Update 3:15pm: Adds Regeneron comment, updates shares. Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 4.5% after a judge denied the company's motion for a preliminary injunction to block an Amgen ...

Regeneron Pharmaceuticals said it is working to determine a path forward for its treatment of several retinal conditions after the Food and Drug Administration said it didn't agree with the ...